This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 969764 results found since Jan 2013.

Multimodal neurophysiological evaluation of primary progressive multiple sclerosis – An increasingly valid biomarker, with limits
Conclusions Multi-modal evoked potential batteries generally show moderate and useful correlation with clinical status as measured by the regulatory standard of EDSS (r=.65 vs. mEPS p<.005) and MSFC (r=.39 vs. mEPS p<.05). The graded qualitative mEPS scoring system displayed the strongest relationship although the influence of scoring system applied appeared reassuringly minimal. Non-association with cognitive impairment is an important limitation however.
Source: Multiple Sclerosis and Related Disorders - October 3, 2015 Category: Neurology Source Type: research

Multiple sclerosis associated genetic variants of CD226 impair regulatory T cell function
Recent association studies have linked numerous genetic variants with an increased risk for multiple sclerosis, although their functional relevance remains largely unknown. Here we investigated phenotypical and functional consequences of a genetic variant in the CD226 gene that, among other autoimmune diseases, predisposes to multiple sclerosis. Phenotypically, effector and regulatory CD4+ memory T cells of healthy individuals carrying the predisposing CD226 genetic variant showed, in comparison to carriers of the protective variant, reduced surface expression of CD226 and an impaired induction of CD226 after stimulation. ...
Source: Brain - October 26, 2015 Category: Neurology Authors: Piedavent-Salomon, M., Willing, A., Engler, J. B., Steinbach, K., Bauer, S., Eggert, B., Ufer, F., Kursawe, N., Wehrmann, S., Jäger, J., Reinhardt, S., Friese, M. A. Tags: Multiple Sclerosis/Neuroinflammation Original Articles Source Type: research

Dysfunction in Multiple Sclerosis: A Scoping Review of the Literature
Conclusions The overall weight of the literature suggests that olfactory dysfunction may occur in MS. Although there is variability in reported frequency, the more robust studies suggest the prevalence is significant, ranging from 20–45% in the MS population. Despite this, the mechanisms are unknown and the clinical relevance of this association has not been well explored. Interesting findings relating mood disorders, cognition, and olfactory dysfunction in MS are also suggested but remain poorly developed and require further investigation. Future studies are also warranted to understand the dynamic changes in olfactory ...
Source: Multiple Sclerosis and Related Disorders - December 4, 2015 Category: Neurology Source Type: research

Olfactory dysfunction in Multiple Sclerosis: A scoping review of the literature
Conclusions The overall weight of the literature suggests that olfactory dysfunction may occur in MS. Although there is variability in reported frequency, the more robust studies suggest the prevalence is significant, ranging from 20% to 45% in the MS population. Despite this, the mechanisms are unknown and the clinical relevance of this association has not been well explored. Interesting findings relating mood disorders, cognition, and olfactory dysfunction in MS are also suggested but remain poorly developed and require further investigation. Future studies are also warranted to understand the dynamic changes in olfactor...
Source: Multiple Sclerosis and Related Disorders - December 12, 2015 Category: Neurology Source Type: research

Quality of Life and Coping Strategies in Lebanese Multiple Sclerosis Patients: A Pilot Study
Publication date: Available online 17 December 2015 Source:Multiple Sclerosis and Related Disorders Author(s): Natali Farran, Diala Ammar, Hala Darwish Coping strategies used by Multiple Sclerosis patients play a key role in adjusting to the disease and affect their overall quality of life. This relationship has been investigated in developed countries, but none has been studied in developing ones such as Lebanon. Factors including barriers to health care delivery, economic pressure and political instability influence which coping strategies are used and often increases the use of negative coping mechanisms. The curre...
Source: Multiple Sclerosis and Related Disorders - December 18, 2015 Category: Neurology Source Type: research

Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in japanese patients with relapsing remitting multiple sclerosis
Conclusions The results of this 2-year study demonstrate that IM IFN beta-1a can be used effectively and safely in Japanese patients with relapsing remitting multiple sclerosis for an extended period of time.
Source: Multiple Sclerosis and Related Disorders - February 3, 2016 Category: Neurology Source Type: research

Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis
Conclusion: From all imaging markers, deep grey matter atrophy and diffuse white matter damage emerged as the strongest predictors for cognitive dysfunction in long-standing multiple sclerosis.
Source: Multiple Sclerosis - March 23, 2016 Category: Neurology Authors: Daams, M., Steenwijk, M. D., Schoonheim, M. M., Wattjes, M. P., Balk, L. J., Tewarie, P. K., Killestein, J., Uitdehaag, B. M., Geurts, J. J., Barkhof, F. Tags: Original Research Papers Source Type: research

Rhabdomyolysis following Interferon-beta Treatment in a Patient with Multiple Sclerosis - a Case Report
Conclusion Clinicians should be aware of the possibility of rhabdomyolysis occurring during Interferon-beta-1-alpha therapy. In cases where patients complain of severe myalgia, and in particular if weakness is reported, creatine kinase activity should be measured to prevent irreversible rhabdomyolysis during Interferon-beta-1-alpha therapy in patients with multiple sclerosis.
Source: Multiple Sclerosis and Related Disorders - May 16, 2016 Category: Neurology Source Type: research

Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis – A case report
Conclusion Clinicians should be aware of the possibility of rhabdomyolysis occurring during Interferon-beta-1-alpha therapy. In cases where patients complain of severe myalgia, and in particular if weakness is reported, creatine kinase activity should be measured to prevent irreversible rhabdomyolysis during Interferon-beta-1-alpha therapy in patients with multiple sclerosis.
Source: Multiple Sclerosis and Related Disorders - May 24, 2016 Category: Neurology Source Type: research

Paleo Diet vs. Sw. Diet for Multiple Sclerosis: Can Either Help Fatigue?
When the National Multiple Sclerosis Society announced last week that it was funding a study on nutrition and MS fatigue, many in the multiple sclerosis world were excited. When those people found out the research was to be conducted by controversial MS figure Terry Wahls, MD, enthusiasm waned for some — but the Society is holding the researchers to very high standards. I look forward to the results in about four years’ time. The study proposes to compare subjects’ standard diet with either the Wahls Protocol (a modified Paleolithic diet) or the Sw. MS Diet (a low-saturated-fat diet) as it relates to MS fatigue. Pr...
Source: Life with MS - August 30, 2016 Category: Neurology Authors: Trevis Gleason Tags: multiple sclerosis MS fatigue MS symptoms multiple sclerosis clinical trials research Symptom management Source Type: blogs

Immunomodulatory therapies delay disease progression in multiple sclerosis
Conclusions: DMDs significantly reduce the risk of multiple sclerosis progression both in patients with initial high-risk and patients with initial low-risk. These findings reinforce the role of DMDs in modifying the natural course of the disease, suggesting that they have a positive effect not only on the inflammatory but also on the neurodegenerative process. The study also confirms the capability of the BREMS score to predict MS evolution.
Source: Multiple Sclerosis - November 3, 2016 Category: Neurology Authors: Bergamaschi, R., Quaglini, S., Tavazzi, E., Amato, M. P., Paolicelli, D., Zipoli, V., Romani, A., Tortorella, C., Portaccio, E., DOnghia, M., Garberi, F., Bargiggia, V., Trojano, M. Tags: Original Research Papers Source Type: research

Abnormal galactosylation of immunoglobulin G in cerebrospinal fluid of multiple sclerosis patients
Background: Glycosylation alterations have been associated with the development of several human diseases and their animal models, including multiple sclerosis. Objectives: We aimed to determine whether immunoglobulin G galactosylation might be changed in multiple sclerosis. Methods: Immunoglobulin G was isolated from serum and cerebrospinal fluid of patients with multiple sclerosis or viral meningitis and control patients without history of inflammatory or autoimmune disease. A lectin-based assay was used to investigate potential galactosylation modifications of immunoglobulin G. Results and conclusion: Galactosylation...
Source: Multiple Sclerosis - December 8, 2016 Category: Neurology Authors: Decker, Y., Schomburg, R., Nemeth, E., Vitkin, A., Fousse, M., Liu, Y., Fassbender, K. Tags: Original Research Papers Source Type: research

The Importance of Stretching With Multiple Sclerosis
I’ve said in more than one blog that I consider myself to be a healthy person who happens to live with multiple sclerosis (MS). “Healthy,” perhaps, but lately I’ve found myself significantly out of shape. With all that 2016 has brought upon me, I decided to ask my wife, Caryn, for help in getting onto a stretching program to help with the things that MS has thrown my way. How to Stretch With MS The National Multiple Sclerosis Society (NMSS) has set out the following guidelines for people with MS as we get into a stretching routine: Stretch on a daily basis, as much as is possible. Include muscle groups that are ti...
Source: Life with MS - December 15, 2016 Category: Neurology Authors: Trevis Gleason Tags: multiple sclerosis life with MS Living with MS MS doctors MS Fitness trevis gleason Source Type: blogs

The RADIANCE and SUNBEAM phase 3 studies of ozanimod in relapsing multiple sclerosis: study design and baseline characteristics (P6.344)
Conclusions:Patient characteristics in RADIANCE Part B and SUNBEAM are consistent with the general RMS population. These phase 3 study results will characterize the efficacy/safety of ozanimod vs. IFNB-1a.Study Supported by: These studies were sponsored by Receptos, a wholly owned subsidiary of Celgene Corporation.Disclosure: Dr. Cree has received personal compensation for activities with AbbVie, Biogen, EMD Serono, Novartis and Shire as a consultant. Dr. Selmaj received personal compensation for activities with Biogen, Novartis, TEVA, Roche, Genzyme, Synthon, Receptos, and Bayer. Dr. Kopicko has received personal compensa...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Cree, B., Selmaj, K., Kopicko, J., Ziemssen, T., De Stefano, N., Bar-Or, A., Comi, G., Arnold, D., Steinman, L., Hartung, H.-P., Montalban, X., Havrdova, E., Kappos, L., Cohen, J. Tags: Disease Modifying Therapy for Multiple Sclerosis: Efficacy and Clinical Trial Outcomes I Source Type: research

Amyloid PET in pseudotumoral multiple sclerosis
Conclusion We report the findings of amyloid PET in a patient with pseudotumoral multiple sclerosis. This case provides further evidence on the role of amyloid PET in the assessment of white matter and demyelinating diseases.
Source: Multiple Sclerosis and Related Disorders - July 7, 2017 Category: Neurology Source Type: research